Mindbio Therapeutics Corp. (TSE:MBIO) has released an update.
MindBio Therapeutics Corp. has completed the final milestone of its Phase 2A microdosing depression clinical trial, demonstrating a significant reduction in depressive symptoms with its lead drug, MB22001. The company is advancing further with multiple Phase 2B trials, including a groundbreaking trial approved for take-home use of MB22001. As one of the few public companies progressing in psychedelic medicines, MindBio stands out on the Canadian Securities Exchange.
For further insights into TSE:MBIO stock, check out TipRanks’ Stock Analysis page.
